Oral Cancer Patients Face Worse Outcomes With Delayed Radiation Therapy
(MedPage Today) -- MONTREAL – Most patients in a Canadian cohort had prolonged times to postoperative radiation therapy, and those delays were associated with worse survival outcomes, a multicenter study showed.
Among 1,368 postsurgical... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 10, 2023 Category: Hematology Source Type: news
Brushing, Flossing Could Help Shield Your Brain From Dementia
THURSDAY, July 6, 2023 -- Add risk of developing memory problems later in life to the list of consequences linked to poor oral health.
Not taking care of your mouth and teeth has already been associated with heart disease, diabetes, certain cancers... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 6, 2023 Category: General Medicine Source Type: news
PET/CT radiomics help with multiple myeloma prognosis
Radiomics models based on F-18 FDG-PET/CT imaging features and powered by machin...Read more on AuntMinnie.comRelated Reading:
SNMMI: Experts debate AI's role in nuclear medicine
PET/CT shows value in patients with portal vein thrombosis
SNMMI: PET tracer describes clear cell renal cancer
SNMMI: New technology improves whole-body PET image quality
PET predicts 'dry mouth' side effect in radiotherapy patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 30, 2023 Category: Radiology Source Type: news
Video from SNMMI: PET tracer shows promise for adrenal gland tumors
CHICAGO - In this interview with AuntMinnie.com at the Society of Nuclea...Read more on AuntMinnie.comRelated Reading:
PET predicts 'dry mouth' side effect in radiotherapy patients
PET/MRI shows promise for breast cancer imaging
SNMMI highlights prostate cancer study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 29, 2023 Category: Radiology Source Type: news
PET tracer images brain cholesterol metabolism
Researchers are highlighting a new PET radiotracer that they say can improv...Read more on AuntMinnie.comRelated Reading:
PET predicts 'dry mouth' side effect in radiotherapy patients
Facial recognition can be thwarted on PET images
PET/MRI shows promise for breast cancer imaging
PET/MRI emerges as a valuable theranostics technology
Earlier diagnostics enables faster Alzheimer's treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 25, 2023 Category: Radiology Source Type: news
PET predicts 'dry mouth' side effect in radiotherapy patients
PET/CT scans taken midway through radiotherapy in head and neck cancer patient...Read more on AuntMinnie.comRelated Reading:
Second-look PET/CT catches cancer spread
PET/CT shows promise predicting outcomes in head, neck cancer
Can 3D-printed shields protect patients during radiation therapy?
PSMA-PET reveals new salivary glands
PET/MRI boosts cancer detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 23, 2023 Category: Radiology Source Type: news
FDA Approves Talazoparib for Metastatic Prostate Cancer FDA Approves Talazoparib for Metastatic Prostate Cancer
The oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene –mutated metastatic castration-resistant prostate cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Pfizer & #039;s TALZENNA ® in combination with XTANDI® receives U.S. FDA approval
Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). (Source: World Pharma News)
Source: World Pharma News - June 21, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Pfizer ’s Talzenna (talazoparib) in Combination with Xtandi (enzalutamide) Receives U.S. FDA Approval for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
NEW YORK--(BUSINESS WIRE) June 20, 2023 -- Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 20, 2023 Category: Drugs & Pharmacology Source Type: news
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
TUESDAY, June 6, 2023 -- Direct oral anticoagulant (DOAC) treatment is noninferior to low-molecular-weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) in cancer patients, according to a study published online June 2 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2023 Category: Pharmaceuticals Source Type: news
Maxillary OCC Mimicking Nonhealing Extraction Sockets Maxillary OCC Mimicking Nonhealing Extraction Sockets
This article presents an interesting case of oral carcinoma cuniculatum of the maxillary molar region. How was this case accurately diagnosed?ePlasty (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2023 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
NYSE American notifies Navidea of listing noncompliance
The New York Stock Exchange (NYSE) American, formerly known as the America...Read more on AuntMinnie.comRelated Reading:
Navidea to sell $8M milestone payment
Navidea posts deep Q3 revenue decreases
Navidea posts revenue declines, net loss increases in Q2
Navidea highlights research on melanoma, oral cancer
Navidea touts clinical study using PET/CT for HIV infection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 5, 2023 Category: Radiology Source Type: news
New Drug Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
New Experimental Drug, Vorasidenib, Could Be Advance Against Glioma Brain Tumors
MONDAY, June 5, 2023 -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2023 Category: General Medicine Source Type: news
Adaptive RT Fails to Relieve Dry Mouth in Head and Neck Cancer
(MedPage Today) -- Use of weekly adaptive radiotherapy (RT) failed to decrease xerostomia (dry mouth) in oropharyngeal cancer patients when compared with standard intensity-modulated RT (IMRT), the phase III ARTIX trial found.
Of the 131 patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 1, 2023 Category: Hematology Source Type: news
